ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

ClinicalTrials.gov ID: NCT02143726

Public ClinicalTrials.gov record NCT02143726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Study identification

NCT ID
NCT02143726
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Enrollment
35 participants

Conditions and interventions

Interventions

  • everolimus Drug
  • sorafenib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 8, 2014
Primary completion
Jan 27, 2021
Completion
Aug 5, 2028
Last update posted
Feb 10, 2026

2014 – 2028

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
Mayo Clinic in Florida Jacksonville Florida 32224-9980
Northwestern University Chicago Illinois 60611
Siouxland Regional Cancer Center Sioux City Iowa 51101
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Mayo Clinic Rochester Minnesota 55905
Nebraska Methodist Hospital Omaha Nebraska 68114
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Bergen Montvale New Jersey 07645
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Sleepy Hollow Sleepy Hollow New York 10591
Memorial Sloan Kettering Nassau Uniondale New York 11553
Southeastern Medical Oncology Center-Clinton Clinton North Carolina 28328
Southeastern Medical Oncology Center-Goldsboro Goldsboro North Carolina 27534
Wayne Memorial Hospital Goldsboro North Carolina 27534
Southeastern Medical Oncology Center-Jacksonville Jacksonville North Carolina 28546
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Mercy Health System Janesville Wisconsin 53547

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02143726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02143726 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →